skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Sepriano, Alexandre ; Kerschbaumer, Andreas ; Smolen, Josef S ; van der Heijde, Désirée ; Dougados, Maxime ; van Vollenhoven, Ronald ; McInnes, Iain B ; Bijlsma, Johannes W ; Burmester, Gerd R ; de Wit, Maarten ; Falzon, Louise ; Landewé, Robert

Annals of the rheumatic diseases, 2020-06, Vol.79 (6), p.760-770 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
  • Título:
    Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
  • Autor: Sepriano, Alexandre ; Kerschbaumer, Andreas ; Smolen, Josef S ; van der Heijde, Désirée ; Dougados, Maxime ; van Vollenhoven, Ronald ; McInnes, Iain B ; Bijlsma, Johannes W ; Burmester, Gerd R ; de Wit, Maarten ; Falzon, Louise ; Landewé, Robert
  • Assuntos: Bias ; Biological products ; Clinical trials ; Drugs ; Herpes zoster ; Infections ; Intervention ; Intestine ; Janus kinase ; Literature reviews ; Population ; Rheumatoid arthritis ; Safety ; Studies ; Systematic review ; Task forces ; Thromboembolism ; Tuberculosis ; Tumor necrosis factor ; Tumors
  • É parte de: Annals of the rheumatic diseases, 2020-06, Vol.79 (6), p.760-770
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Undefined-1
    ObjectType-Feature-3
    content type line 23
  • Descrição: ObjectivesTo perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).MethodsAn SLR of observational studies comparing safety outcomes of any DMARD with another intervention for the management of RA. A comparator group was required for inclusion. For treatments still without registry data (eg, sarilumab and the Janus kinase (JAK) inhibitors baricitinib, upadacitinib), randomised controlled trials (RCTs) and long-term extensions (LTEs) were used. Risk of bias (RoB) was assessed according to standard procedures.ResultsForty-two observational studies fulfilled the inclusion criteria, addressing safety outcomes with bDMARDs and sDMARDs. Nine studies showed no difference in the risk of serious infections across bDMARDs and two studies (high RoB) showed an increased risk with bDMARDs compared with conventional synthetic (cs) DMARDs (adjusted incidence rate ratio 3.1–3.9). The risk of Herpes zoster infection was similar across bDMARDs, but one study showed an increased risk with tofacitinib compared with abatacept (adjusted HR (aHR) 2.0). Five studies showed no increased risk of cancer for bDMARDs compared with csDMARDs. An increased risk of lower intestinal perforation was found for tocilizumab compared with csDMARDs (aHR 4.5) and tumour necrosis factor inhibitor (TNFi) (aHR 2.6–4.0). Sixty manuscripts reported safety data from RCTs/LTEs. Overall, no unexpected safety outcomes were found, except for the possibly increased risk of venous thromboembolism (VTE) with JAK inhibitors.ConclusionData obtained by this SLR confirm the known safety profile of bDMARDs. The risk of VTE in RA, especially in patients on JAK inhibitors, needs further evaluation.
  • Editor: England: BMJ Publishing Group LTD
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  3 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.